Acloproxalap is a quinoline-based aldede scavenger that can be used in studies of diseases with toxic aldede accumulation, such as inflammatory diseases of the eye and skin, respiratory diseases such as pneumonia, organ diseases, and viral infection-related syndromes[1][2].
Acloproxalap (compound I-6) (100 or 200 mg/kg, i.p. or p.o., everyday, 6 days) can effectively improve inflammation of the colon in acute ulcerative colitis (UC) female Swiss Webster mice[1].
| Animal Model: | Acute ulcerative colitis (UC) in female Swiss Webster mice[1] |
| Dosage: | 100 mg/kg, 200 mg/kg |
| Administration: | Intraperitoneal injection for 100 mg/kg, oral gavage for 200 mg/kg; everyday; 6 days |
| Result: | Inhibited weight loss in intraperitoneal injection mice significantly while there was no significant difference in the oral gavage group compared to the control group. Both significantly reduced colonic histopathological parameters. |
| Animal Model: | Male non-naÏve beagle dogs[2] | ||||||||||||||
| Dosage: | 3 mg/kg | ||||||||||||||
| Administration: | Intravenous injection; once | ||||||||||||||
| Result: | The pharmacokinetic parameters of Acloproxalap (compound I-1)
|
| Animal Model: | Male non-naÏve beagle dogs[2] | ||||||||||||||
| Dosage: | 10 mg/kg | ||||||||||||||
| Administration: | Oral gavage; once | ||||||||||||||
| Result: | The pharmacokinetic parameters of Acloproxalap (compound I-1)
|
[1]. Susan Macdonald, et al. Treatment of inflammatory disorders. US20190105322
[2]. Todd Brady, et al. Pharmaceutical formulations and uses thereof. WO2021231792